Symbols / CRVO
CRVO Chart
About
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 44.32M |
| Enterprise Value | 17.03M | Income | -25.58M | Sales | 6.16M |
| Book/sh | 2.81 | Cash/sh | 2.95 | Dividend Yield | — |
| Payout | 0.00% | Employees | 15 | IPO | — |
| P/E | — | Forward P/E | -2.39 | PEG | — |
| P/S | 7.20 | P/B | 1.70 | P/C | — |
| EV/EBITDA | — | EV/Sales | 2.76 | Quick Ratio | 6.23 |
| Current Ratio | 6.66 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.90 | EPS next Y | -2.01 | EPS Growth | — |
| Revenue Growth | -83.40% | Earnings | 2026-03-19 | ROA | -42.78% |
| ROE | -71.42% | ROIC | — | Gross Margin | -274.58% |
| Oper. Margin | -24.94% | Profit Margin | 0.00% | Shs Outstand | 9.25M |
| Shs Float | 5.49M | Short Float | 3.67% | Short Ratio | 3.02 |
| Short Interest | — | 52W High | 16.94 | 52W Low | 1.92 |
| Beta | -6.23 | Avg Volume | 69.72K | Volume | 63.62K |
| Target Price | $22.43 | Recom | Strong_buy | Prev Close | $4.64 |
| Price | $4.79 | Change | 3.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$22.43
Mean price target
2. Current target
$4.79
Latest analyst target
3. DCF / Fair value
$-29.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.79
Low
$15.00
High
$31.00
Mean
$22.43
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-18 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-12-18 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-12-05 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-12-02 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-11-11 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-11-05 | up | HC Wainwright & Co. | Neutral → Buy | $25 |
| 2025-11-04 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-09-08 | reit | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $31 |
| 2025-08-12 | reit | Roth Capital | Buy → Buy | $16 |
| 2025-08-11 | main | Chardan Capital | Buy → Buy | $15 |
| 2025-08-11 | main | D. Boral Capital | Buy → Buy | $15 |
| 2025-07-29 | main | Canaccord Genuity | Buy → Buy | $27 |
| 2025-07-28 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-07-25 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-11 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-13 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-12 | main | Chardan Capital | Buy → Buy | $15 |
| 2025-03-26 | main | D. Boral Capital | Buy → Buy | $10 |
- $CRVO stock is down 11% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
- CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely - simplywall.st Wed, 18 Feb 2026 10
- UK-backed ALS trial to test CervoMed brain drug neflamapimod - Stock Titan Wed, 18 Feb 2026 11
- Why (CRVO) Price Action Is Critical for Tactical Trading - Stock Traders Daily hu, 29 Jan 2026 17
- CervoMed (CRVO) Analyst Rating Maintained as "Buy" by D. Boral C - GuruFocus Wed, 18 Feb 2026 13
- Here's Why We're Watching CervoMed's (NASDAQ:CRVO) Cash Burn Situation - Yahoo Finance hu, 30 Oct 2025 07
- CervoMed stock soars after positive dementia treatment trial data - Investing.com Wed, 08 Oct 2025 07
- CervoMed Inc. Stock (CRVO) Opinions on Insider Buying and Clinical Trial Progress - Quiver Quantitative Wed, 19 Nov 2025 08
- CervoMed (NASDAQ: CRVO) Phase 2b shows 75% drop in DLB progression risk, eyes Phase 3 - Stock Titan hu, 04 Dec 2025 08
- CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock - Stocktwits Mon, 28 Jul 2025 17
- Liquidity Mapping Around (CRVO) Price Events - Stock Traders Daily Mon, 09 Feb 2026 08
- Cantor Fitzgerald initiates CervoMed stock with Overweight rating - Investing.com hu, 18 Dec 2025 08
- CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Fri, 07 Nov 2025 08
- $CRVO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
- CervoMed (NASDAQ: CRVO) Highlights Phase 2b DLB Biomarker Data on Neflamapimod at CTAD - Stock Titan Mon, 24 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3500 | 29250.0 | — | Purchase at price 8.32 - 8.45 per share. | ELDER WILLIAM ROBERT | General Counsel | — | 2025-11-18 00:00:00 | D |
| 1 | 5000 | 41430.0 | — | Purchase at price 7.95 - 8.43 per share. | WINTON MATTHEW | Officer | — | 2025-11-18 00:00:00 | D |
| 2 | 21600 | 182736.0 | — | Purchase at price 8.46 per share. | GREGOIRE SYLVIE L | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-17 00:00:00 | D/I |
| 3 | 21600 | 182736.0 | — | Purchase at price 8.46 per share. | ALAM JOHN J | Chief Executive Officer | — | 2025-11-17 00:00:00 | D/I |
| 4 | 7847 | 59101.0 | — | Purchase at price 7.51 - 7.57 per share. | GREGOIRE SYLVIE L | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-14 00:00:00 | D/I |
| 5 | 10000 | 75700.0 | — | Purchase at price 7.57 per share. | WINTON MATTHEW | Officer | — | 2025-11-14 00:00:00 | D |
| 6 | 7847 | 59101.0 | — | Purchase at price 7.51 - 7.57 per share. | ALAM JOHN J | Chief Executive Officer | — | 2025-11-14 00:00:00 | D/I |
| 7 | 5553 | 40815.0 | — | Purchase at price 7.35 per share. | GREGOIRE SYLVIE L | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-12 00:00:00 | D |
| 8 | 3500 | 26040.0 | — | Purchase at price 7.44 per share. | ELDER WILLIAM ROBERT | General Counsel | — | 2025-11-12 00:00:00 | D |
| 9 | 5553 | 40815.0 | — | Purchase at price 7.35 per share. | ALAM JOHN J | Chief Executive Officer | — | 2025-11-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -156.27K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.02 |
| NormalizedEBITDA | -18.23M | -7.81M | -5.80M | -7.31M |
| TotalUnusualItems | 0.00 | -8.64M | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | -8.64M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -16.29M | -2.17M | -5.80M | -24.10M |
| ReconciledDepreciation | 0.00 | 93.42K | ||
| EBITDA | -18.23M | -7.81M | -5.80M | -15.94M |
| EBIT | -18.23M | -7.81M | -5.80M | -16.04M |
| NetInterestIncome | 1.94M | 219.43K | 61.64K | 137.49K |
| InterestExpense | 0.00 | 587.00 | ||
| InterestIncome | 1.94M | 219.43K | 62.23K | 137.49K |
| NormalizedIncome | -16.29M | -2.17M | -5.80M | -15.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -16.29M | -2.17M | -5.80M | -24.10M |
| TotalExpenses | 18.23M | 7.81M | 3.48M | 16.04M |
| TotalOperatingIncomeAsReported | -18.23M | -7.81M | -3.48M | -24.68M |
| DilutedAverageShares | 8.07M | 2.66M | 518.14K | 1.30M |
| BasicAverageShares | 8.07M | 2.66M | 518.14K | 1.30M |
| DilutedEPS | -2.02 | -0.82 | -11.20 | -18.57 |
| BasicEPS | -2.02 | -0.82 | -11.20 | -18.57 |
| DilutedNIAvailtoComStockholders | -16.29M | -2.17M | -5.80M | -24.10M |
| NetIncomeCommonStockholders | -16.29M | -2.17M | -5.80M | -24.10M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -16.29M | -2.17M | -5.80M | -24.10M |
| NetIncomeIncludingNoncontrollingInterests | -16.29M | -2.17M | -5.80M | -24.10M |
| NetIncomeContinuousOperations | -16.29M | -2.17M | -5.80M | -24.10M |
| TaxProvision | 0.00 | -443.89K | ||
| PretaxIncome | -16.29M | -2.17M | -5.80M | -24.54M |
| OtherIncomeExpense | -991.00 | 5.42M | -2.39M | -8.64M |
| OtherNonOperatingIncomeExpenses | -991.00 | 5.42M | -2.39M | |
| SpecialIncomeCharges | 0.00 | -8.64M | ||
| ImpairmentOfCapitalAssets | 0.00 | 8.64M | ||
| NetNonOperatingInterestIncomeExpense | 1.94M | 219.43K | 61.64K | 137.49K |
| InterestExpenseNonOperating | 0.00 | 587.00 | ||
| InterestIncomeNonOperating | 1.94M | 219.43K | 62.23K | 137.49K |
| OperatingIncome | -18.23M | -7.81M | -3.48M | -16.04M |
| OperatingExpense | 18.23M | 7.81M | 3.48M | 16.04M |
| OtherOperatingExpenses | -9.74M | -7.14M | ||
| DepreciationAmortizationDepletionIncomeStatement | 0.00 | 93.42K | ||
| DepreciationAndAmortizationInIncomeStatement | 0.00 | 93.42K | ||
| DepreciationIncomeStatement | 0.00 | 93.42K | ||
| ResearchAndDevelopment | 18.80M | 8.44M | 1.34M | 8.50M |
| SellingGeneralAndAdministration | 9.17M | 6.52M | 2.14M | 7.45M |
| GeneralAndAdministrativeExpense | 9.17M | 6.52M | 2.14M | 7.45M |
| OtherGandA | 9.17M | 6.52M | 2.14M | 7.45M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 8.70M | 5.67M | 1.36M | 1.36M |
| ShareIssued | 8.70M | 5.67M | 1.36M | 1.36M |
| NetDebt | 8.32M | |||
| TotalDebt | 12.41M | 0.00 | ||
| TangibleBookValue | 39.20M | 7.38M | -33.29M | 34.91M |
| InvestedCapital | 39.20M | 7.38M | -20.87M | 34.91M |
| WorkingCapital | 39.20M | 7.37M | -9.00M | 34.90M |
| NetTangibleAssets | 39.20M | 7.38M | -33.29M | 34.91M |
| CapitalLeaseObligations | 0.00 | |||
| CommonStockEquity | 39.20M | 7.38M | -33.29M | 34.91M |
| TotalCapitalization | 39.20M | 7.38M | -33.29M | 34.91M |
| TotalEquityGrossMinorityInterest | 39.20M | 7.38M | -33.29M | 34.91M |
| StockholdersEquity | 39.20M | 7.38M | -33.29M | 34.91M |
| GainsLossesNotAffectingRetainedEarnings | 56.20K | 0.00 | -35.38K | 0.00 |
| OtherEquityAdjustments | 56.20K | -35.38K | ||
| RetainedEarnings | -70.73M | -54.44M | -52.27M | -130.01M |
| AdditionalPaidInCapital | 109.87M | 61.81M | 18.98M | 164.91M |
| CapitalStock | 8.70K | 5.67K | 518.00 | 2.04K |
| CommonStock | 8.70K | 5.67K | 518.00 | 2.04K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 3.88M | 2.60M | 37.44M | 2.93M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 24.29M | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 24.29M | ||
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | |||
| LongTermCapitalLeaseObligation | 0.00 | |||
| CurrentLiabilities | 3.88M | 2.60M | 13.16M | 2.93M |
| OtherCurrentLiabilities | 115.88K | 88.66K | 129.85K | 65.94K |
| CurrentDebtAndCapitalLeaseObligation | 12.41M | |||
| CurrentCapitalLeaseObligation | 0.00 | |||
| CurrentDebt | 12.41M | |||
| OtherCurrentBorrowings | 12.41M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 803.19K | 1.03M | 364.07K | |
| PayablesAndAccruedExpenses | 2.96M | 1.48M | 377.48K | 2.86M |
| CurrentAccruedExpenses | 1.41M | 698.11K | 280.18K | 1.91M |
| Payables | 1.55M | 782.93K | 97.30K | 947.50K |
| TotalTaxPayable | 40.46K | 120.46K | 0.00 | |
| AccountsPayable | 1.51M | 662.47K | 97.30K | 947.50K |
| TotalAssets | 43.08M | 9.97M | 4.16M | 37.84M |
| TotalNonCurrentAssets | 0.00 | 7.77K | 0.00 | 15.58K |
| OtherNonCurrentAssets | 7.77K | 15.58K | ||
| GoodwillAndOtherIntangibleAssets | 0.00 | |||
| NetPPE | 0.00 | |||
| GrossPPE | 0.00 | |||
| CurrentAssets | 43.08M | 9.96M | 4.16M | 37.82M |
| OtherCurrentAssets | 112.41K | 510.01K | ||
| PrepaidAssets | 1.91M | 1.26M | 64.13K | 510.01K |
| Receivables | 2.25M | 915.40K | 0.00 | |
| OtherReceivables | 2.25M | 915.40K | ||
| CashCashEquivalentsAndShortTermInvestments | 38.92M | 7.79M | 4.09M | 37.31M |
| OtherShortTermInvestments | 29.92M | 0.00 | 12.41M | 0.00 |
| CashAndCashEquivalents | 9.00M | 7.79M | 4.09M | 37.31M |
| CashEquivalents | 7.79M | 4.09M | 7.01M | |
| CashFinancial | 1.59M | 30.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.53M | -7.45M | -2.57M | -14.50M |
| IssuanceOfCapitalStock | 46.40M | 810.00K | 0.00 | 31.09M |
| EndCashPosition | 9.00M | 7.79M | 4.09M | 37.31M |
| BeginningCashPosition | 7.79M | 4.09M | 6.67M | 18.52M |
| ChangesInCash | 1.21M | 3.70M | -2.57M | 18.80M |
| FinancingCashFlow | 46.40M | 11.15M | 0.00 | 33.30M |
| CashFlowFromContinuingFinancingActivities | 46.40M | 11.15M | 0.00 | 33.30M |
| NetOtherFinancingCharges | 10.34M | |||
| ProceedsFromStockOptionExercised | 0.00 | 2.20M | ||
| NetPreferredStockIssuance | 5.00K | 0.00 | ||
| PreferredStockIssuance | 5.00K | 0.00 | ||
| NetCommonStockIssuance | 46.40M | 810.00K | 0.00 | 31.09M |
| CommonStockIssuance | 46.40M | 810.00K | 0.00 | 31.09M |
| InvestingCashFlow | -28.66M | 0.00 | -12.24M | 4.00K |
| CashFlowFromContinuingInvestingActivities | -28.66M | 0.00 | -12.24M | 4.00K |
| NetInvestmentPurchaseAndSale | -28.66M | 0.00 | -12.24M | 0.00 |
| SaleOfInvestment | 19.44M | 0.00 | 25.75M | 0.00 |
| PurchaseOfInvestment | -48.10M | 0.00 | -37.99M | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | 4.00K | ||
| SaleOfPPE | 0.00 | 4.00K | ||
| OperatingCashFlow | -16.53M | -7.45M | -2.57M | -14.50M |
| CashFlowFromContinuingOperatingActivities | -16.53M | -7.45M | -2.57M | -14.50M |
| ChangeInWorkingCapital | -440.66K | -261.36K | 379.94K | 356.37K |
| ChangeInPayablesAndAccruedExpense | 1.54M | 1.85M | 294.83K | 605.37K |
| ChangeInAccruedExpense | 690.29K | 1.29M | 215.68K | |
| ChangeInPayable | 848.97K | 565.17K | 79.15K | 605.37K |
| ChangeInAccountPayable | 848.97K | 565.17K | 79.15K | 605.37K |
| ChangeInPrepaidAssets | -641.09K | -1.20M | 85.10K | -249.00K |
| ChangeInReceivables | -1.34M | -915.40K | 0.00 | |
| StockBasedCompensation | 1.41M | 407.63K | 333.83K | 897.26K |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -5.42M | 2.39M | |
| AmortizationOfSecurities | -1.21M | 0.00 | -208.58K | 0.00 |
| DeferredTax | 0.00 | -443.89K | ||
| DeferredIncomeTax | 0.00 | -443.89K | ||
| DepreciationAmortizationDepletion | 0.00 | 93.42K | ||
| DepreciationAndAmortization | 0.00 | 93.42K | ||
| Depreciation | 93.42K | |||
| OperatingGainsLosses | 127.52K | 8.69M | ||
| PensionAndEmployeeBenefitExpense | 0.00 | 127.52K | ||
| GainLossOnSaleOfPPE | 0.00 | 8.69M | ||
| NetIncomeFromContinuingOperations | -16.29M | -2.17M | -5.80M | -24.10M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRVO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|